We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Read MoreHide Full Article
Key Takeaways
{\"0\":\"HIMS appoints Mo Elshenawy as CTO to accelerate its AI-powered digital health platform strategy.\",\"1\":\"Hims & Hers\' recent $870 million convertible notes raise will fund AI, diagnostics and global tech expansion.\",\"2\":\"HIMS leverages proprietary algorithms and cloud systems to scale personalized virtual care delivery.\"}
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is actively deepening its technology integration to transform how healthcare is delivered. The company recently appointed Mo Elshenawy as chief technology officer (CTO) to accelerate its push into AI-driven healthcare. HIMS intends to build the next-generation platform where diagnosis, treatment and delivery are seamlessly connected, with AI serving as a key enabler of personalization and scalability. This shift reflects Hims & Hers’ strategy of embedding AI across its operations, from intake and intelligent routing systems to diagnostics and tailored treatment recommendations, aiming to make care more efficient, accessible and individualized.
Hims & Hers’ financial moves also underscore its commitment to technology. In May 2025, it completed an $870 million convertible notes offering, with proceeds earmarked for global expansion and significant investment in AI, diagnostics and personalized treatments. This capital will likely bolster the work of its technology team, particularly in expanding its data pipeline and developing new AI tools to refine the consumer experience. Alongside internal advancements, acquisitions such as ZAVA and new facilities in pharmacy, compounding and lab services enhance Hims & Hers’ ability to integrate technology into the broader healthcare value chain.
Hims & Hers emphasizes its proprietary algorithms, customizable technology stack and cloud-based fulfillment systems as the backbone of its platform. These systems enable scalable telehealth consultations, subscription-based prescription fulfillment and personalized care management, supported by affiliated medical groups and digital pharmacies. By combining AI-driven personalization with vertically integrated infrastructure, Hims & Hers positions itself to deliver cost-effective, high-quality care at scale, while also preparing for new opportunities in weight loss, mental health and other chronic conditions.
GDRX & TDOC’s Tech-Enabled Platforms Advancing Accessible Digital Care
GoodRx Holdings, Inc. (GDRX - Free Report) integrates technology by leveraging a data-driven platform that connects millions of consumers with affordable prescription options. GoodRx utilizes proprietary algorithms to match users with savings opportunities and relies on mobile and web interfaces to deliver seamless experiences. The company also integrates telehealth services through GoodRx Care, expanding its digital footprint while employing analytics to optimize engagement across prescription transactions, subscriptions and manufacturer solutions.
Teladoc Health, Inc. (TDOC - Free Report) integrates technology through a scalable API-driven platform that supports up to 100,000 visits per day, combining AI, machine learning and cloud-based tools. Teladoc Health’s platform enables connected devices, such as its FDA-cleared blood glucose meter, to sync patient data with real-time AI-powered nudges. Additionally, Teladoc Health integrates deeply with electronic medical records, payors and hospital systems, enhancing connectivity and personalization across its global virtual care network.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 123.2% year to date, outperforming the industry’s growth of 28.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.6X is lower than the industry’s average of 6X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is actively deepening its technology integration to transform how healthcare is delivered. The company recently appointed Mo Elshenawy as chief technology officer (CTO) to accelerate its push into AI-driven healthcare. HIMS intends to build the next-generation platform where diagnosis, treatment and delivery are seamlessly connected, with AI serving as a key enabler of personalization and scalability. This shift reflects Hims & Hers’ strategy of embedding AI across its operations, from intake and intelligent routing systems to diagnostics and tailored treatment recommendations, aiming to make care more efficient, accessible and individualized.
Hims & Hers’ financial moves also underscore its commitment to technology. In May 2025, it completed an $870 million convertible notes offering, with proceeds earmarked for global expansion and significant investment in AI, diagnostics and personalized treatments. This capital will likely bolster the work of its technology team, particularly in expanding its data pipeline and developing new AI tools to refine the consumer experience. Alongside internal advancements, acquisitions such as ZAVA and new facilities in pharmacy, compounding and lab services enhance Hims & Hers’ ability to integrate technology into the broader healthcare value chain.
Hims & Hers emphasizes its proprietary algorithms, customizable technology stack and cloud-based fulfillment systems as the backbone of its platform. These systems enable scalable telehealth consultations, subscription-based prescription fulfillment and personalized care management, supported by affiliated medical groups and digital pharmacies. By combining AI-driven personalization with vertically integrated infrastructure, Hims & Hers positions itself to deliver cost-effective, high-quality care at scale, while also preparing for new opportunities in weight loss, mental health and other chronic conditions.
GDRX & TDOC’s Tech-Enabled Platforms Advancing Accessible Digital Care
GoodRx Holdings, Inc. (GDRX - Free Report) integrates technology by leveraging a data-driven platform that connects millions of consumers with affordable prescription options. GoodRx utilizes proprietary algorithms to match users with savings opportunities and relies on mobile and web interfaces to deliver seamless experiences. The company also integrates telehealth services through GoodRx Care, expanding its digital footprint while employing analytics to optimize engagement across prescription transactions, subscriptions and manufacturer solutions.
Teladoc Health, Inc. (TDOC - Free Report) integrates technology through a scalable API-driven platform that supports up to 100,000 visits per day, combining AI, machine learning and cloud-based tools. Teladoc Health’s platform enables connected devices, such as its FDA-cleared blood glucose meter, to sync patient data with real-time AI-powered nudges. Additionally, Teladoc Health integrates deeply with electronic medical records, payors and hospital systems, enhancing connectivity and personalization across its global virtual care network.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 123.2% year to date, outperforming the industry’s growth of 28.1%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.6X is lower than the industry’s average of 6X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 122.2% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.